NASDAQ:PRFX

Painreform Stock Insider Trading

Healthcare > Drug Manufacturers - Specialty & Generic

Buy PRFX

*Your capital is at risk

$1.60

-0.0500 (-3.03%)

At Close: Jun 22, 2026

PainReform Stock Insider Power

Based on the 19 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 33.49K and sold 0 PRFX shares in the last 19 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 19 transactions)	100.00
● Buy	33.49K shares
● Sell	0 shares
100% Buy Activity Weak Negative Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)	Aviel Sigal Chief Operating Officer	C-Suite Officer	43 Value: $12.4K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)(1)( 2)	Aviel Sigal Chief Operating Officer	C-Suite Officer	104 Value: $71.1K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)(1)( 2)	Aviel Sigal Chief Operating Officer	C-Suite Officer	612 Value: $18.4K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)(1)( 2)	Aviel Sigal Chief Operating Officer	C-Suite Officer	3 000 Value: $47.3K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)	Baron Ellen S Director	Director	50 Value: $270.0K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)	Baron Ellen S Director	Director	183 Value: $5K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)	Cohen-arazi Efraim Interim CEO	CEO / President	50 Value: $270.0K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)(1)( 2)	Cohen-arazi Efraim Interim CEO	CEO / President	150 Value: $106.0K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)(1)( 2)	Cohen-arazi Efraim Interim CEO	CEO / President	183 Value: $5K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)(1)( 2)	Cohen-arazi Efraim Interim CEO	CEO / President	3 000 Value: $47.3K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)	Geller Ehud Exec Chairman Of The Board	CEO / President	50 Value: $270.0K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)	Geller Ehud Exec Chairman Of The Board	CEO / President	183 Value: $5K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)	Geller Ehud Exec Chairman Of The Board	CEO / President	20 314 Value: $1K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)	Geller Ehud Exec Chairman Of The Board	CEO / President	150 Value: $106.0K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)	Broder Eyal Chief Financial Officer	C-Suite Officer	180 Value: $5K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)(1)( 2)	Broder Eyal Chief Financial Officer	C-Suite Officer	2 000 Value: $31.5K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)	Lawlor Augustine Director	Director	50 Value: $270.0K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)	Lawlor Augustine Director	Director	183 Value: $5K
Mar 18, 2026 Buy	Employee Stock Option (Right to Buy)	Shavit Asaf Director	Director	3 000 Value: $16.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PAINREFORM LTD.

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the tre...

Read Full Profile Here